01—Abstract
Summary
Summary of the 10-K filed February 28, 2022. Cited figures are marked; the original filing is the authoritative source.
This Form 10-K covers fiscal year 2021 for BeiGene, Ltd. (NASDAQ: BGNE; HKEx: 06160; STAR Market: 688235).
The filing was made February 28, 2022. The user's request refers to "BeOne Medicines Ltd. (ONC)," but the document itself is BeiGene's annual report. BeiGene is the predecessor name of the company now known as BeOne Medicines.
Total revenue rose 280.8% to $1.18 billiona, driven by $542.3 million of collaboration revenue, mainly the $484.6 million license recognized under the January 2021 Novartis tislelizumab agreement. Product revenue grew 105% to $634.0 million, led by tislelizumab ($255.1 million in China), BRUKINSA ($218.0 million globally, including $115.7 million in the U.S.), and in-licensed Amgen products. Despite the revenue step-up, the company posted a net loss of $1.41 billion, versus $1.60 billion in 2020, and an accumulated deficit of $5.0 billion.
R&D expense was $1.46 billionb and SG&A was $990 million as the company scaled its global commercial and clinical organizations. The balance sheet was strengthened substantially during the year. The December 2021 STAR Market offering raised about $3.4 billion net, and total cash, cash equivalents, and restricted cash reached $4.38 billion, with another $2.24 billion in short-term U.S. Treasury investments.
Against $629.7 millionc of debt, the company said existing resources should fund operations for at least 12 months. Operating cash burn was still about $1.3 billion in 2021. Gross margin on product sales declined to 74.0% from 77.1%, mainly because of National Reimbursement Drug List (NRDL) price reductions and roughly $57.5 million of distributor compensation for pre-NRDL inventory.
Key investor considerations include the company's dependence on China pricing policy (NRDL inclusion and volume-based procurement), its continued losses, the arbitration with BMS over ABRAXANE supply and license termination, and the Holding Foreign Companies Accountable Act (HFCA) risk arising from the PCAOB's inability to inspect its China-based auditor. These factors are balanced by the Novartis upfront payments ($650 milliond received in 2021, $300 million received in January 2022 for ociperlimab) and the expanding BRUKINSA and tislelizumab footprint.
02—Key points
Key Highlights
- Total revenue rose 280.8% to $1.18 billion, including $542.3 million of collaboration revenue, primarily the Novartis tislelizumab license recognized in 2021.
- Product revenue grew 105% to $634.0 million: tislelizumab $255.1 million, BRUKINSA $218.0 million (U.S. $115.7 million, up from $18.2 million), and Amgen-licensed XGEVA and BLINCYTO in China.
- Net loss narrowed to $1.41 billion from $1.60 billion, but the accumulated deficit reached $5.0 billion and operating cash outflow was $1.3 billion.
- Liquidity is strong: about $4.4 billion of cash and restricted cash plus $2.2 billion of short-term investments, supported by roughly $3.4 billion net from the STAR Market offering in December 2021.
- Product gross margin fell to 74.0% from 77.1%, reflecting NRDL price cuts and about $57.5 million of distributor compensation for pre-NRDL inventory.
- Pipeline and partnering momentum: ociperlimab (TIGIT) option deal with Novartis ($300 million upfront received January 2022), BGB-11417 pivotal trials expected in 2022, and multiple zanubrutinib filings pending in the U.S., EU, and China.
- Material risks include China pricing and reimbursement policy, the ABRAXANE arbitration against BMS, and PCAOB inspection exposure under the HFCA Act that could affect U.S. listing status.
03—One dollar
Follow one dollar
For each $1.00 of revenue in FY2021, BeOne Medicines Ltd. lost $1.24.
- Revenue$1.18B100.0%
- Cost of revenue−$164.9M14.0%
- Gross profit$1.01B86.0%
- Operating costs−$2.45B208.3%
- Operating income−$1.44B122.3%
- Interest, other & tax−$19.1M1.6%
- Net income−$1.46B123.9%
04—Financials
Financial Highlights
Figures from 10-KFY2021filed February 28, 2022Financial Statements
FY2021 against FY2020
| Line item | FY2021FY2020 | Change |
|---|---|---|
| Revenue | $1.18B$308.87M | +280.8% |
| Cost of Revenue | $164.91M$70.66M | +133.4% |
| Gross Profit | $1.01B$238.22M | +324.6% |
| R&D Expenses | $1.46B$1.29B | +12.7% |
| SG&A Expenses | $990.12M$600.18M | +65.0% |
| Operating Expenses | $2.45B$1.97B | +24.6% |
| Operating Income | -$1.44B-$1.66B | +13.2% |
| Interest Expense | $29.26M$18.31M | +59.8% |
| Net Income | -$1.46B-$1.63B | +10.5% |
| EPS (Basic) | $-1.21$-1.47 | +17.7% |
| EPS (Diluted) | $-1.21$-1.50 | +19.3% |
| Shares Outstanding (Basic) | 1.21B1.09B | +11.2% |
| Shares Outstanding (Diluted) | 1.21B1.09B | +11.2% |
05—Questions
Frequently Asked Questions
How much of 2021 revenue was recurring product sales versus one-time collaboration payments?
Product revenue was $634.0 million (54% of total), and collaboration revenue was $542.3 million (46%). The collaboration amount is largely non-recurring: $484.6 million was license revenue recognized when the tislelizumab license was delivered to Novartis. The remaining $53.7 million was R&D services revenue, recognized over time, and $4.0 million was right-to-access revenue for ociperlimab. Investors should expect the collaboration line to be lumpy and tied to deal timing.
Why did gross margin decline, and is it likely to recover?
Gross margin on product sales fell to 74.0% from 77.1%. The company attributed the decline to roughly $57.5 million of distributor compensation for inventory sold at pre-NRDL prices, plus the lower prices that follow NRDL listing. Partial offsets came from a richer mix of higher-margin BRUKINSA and tislelizumab sales. Margin recovery depends on whether price reductions stabilize and whether the mix continues to shift toward proprietary products rather than lower-margin in-licensed sales.
How long can the company fund operations without new capital?
Management stated that existing cash, cash equivalents, and short-term investments, about $6.6 billion including the STAR offering proceeds, should be sufficient for at least 12 months from the financial statement issuance date. Total debt was $629.7 million, with $427.6 million due within a year. However, the company also said its resources may not be enough to complete all global development and launch plans, so future equity or debt financing remains possible.
What are the main regulatory risks tied to China?
China is the company's largest market for product revenue. Key risks include NRDL price negotiations and volume-based procurement, which can cut prices or exclude products from public hospitals (VIDAZA was affected). The company also faces the NMPA's suspension of ABRAXANE imports in 2020, and the PCAOB's inability to inspect its auditor in China. That inspection gap could lead to delisting under the HFCA Act if not resolved within the statutory period, creating meaningful uncertainty for ADS holders.
What is the ABRAXANE dispute with BMS?
After the NMPA suspended ABRAXANE in China in March 2020 following inspection findings at BMS's U.S. contract manufacturer, BeiGene initiated ICC arbitration against BMS for breach of the license and supply agreement. BMS counterclaimed for about $17 million of recall costs. In October 2021, BMS gave notice purporting to terminate the license, which BeiGene disputes. ABRAXANE generated no sales after the suspension, so the financial exposure is primarily the outcome of the arbitration, with a hearing scheduled for June 2022.
06—Continue